Compare Kohl's Corporation (KSS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Summit Therapeutics Inc — how do they compare? Kohl's Corporation trades at $20.36 (market cap $2.28B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 6× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Summit Therapeutics Inc for 16 Days on average.
| KSS | SMMT | |
|---|---|---|
Market Cap | $2.28B | $13.71B |
Volume | 4,960,280 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $26.38 |
52-Week Low | $11.72 | $12.43 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | $7.88B | $13.04B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.28, up 0.8% with a bullish technical signal despite overbought RSI readings. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and raised guidance signal operational improvement. However, revenue has declined for 18 consecutive quarters, presenting a challenging growth environment.
The investment case balances deep value against persistent sales declines. While low valuations and margin improvements support upside potential, sustained revenue weakness and competitive pressures remain key risks. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
